Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Type 2 diabetes mellitus is a progressive disease requiring regular monitoring and therapeutic changes. It is important that healthcare professionals embrace both ends of the spectrum of therapeutic inertia, including appropriate advancement and de-intensification of therapies.
Artificial intelligence has already revolutionized various fields in medicine and research. Due to the complex and interconnected nature of the endocrine system, it is an ideal area to further exploit and maximize the potential benefits of artificial intelligence.
Our lives are governed by three clocks: the social clock that organizes our lives with others (local time), the biological clock that controls our physiology (circadian time) and the sun clock that defines natural light and darkness. The more misaligned these clocks are, the higher our odds of developing certain diseases. ‘Social jetlag’ quantifies the difference between local and circadian time.
This Review outlines our current understanding of the biogenesis and functions of lipid droplets in health and disease, highlighting a key role for lipid droplet biogenesis in alleviating cellular stress.
An urgent need exists for technologies and devices capable of frequent and real-time insulin measurements in patients with diabetes mellitus to guide optimal insulin dosing. This Perspective discusses the advances and challenges in moving insulin assays from laboratory-based assays to frequent and continuous measurements in decentralized settings.
The path to becoming a clinical academic researcher is arduous and convoluted, with many hurdles. A good mentor is key to growth and development, not only as one embarks on the journey, but also as a ‘sounding board’ throughout one’s career.
Type 1 diabetes mellitus (T1DM) can be predicted, and immune therapy can alter the progression of the disease. The FDA’s approval of teplizumab as the first disease-modifying therapy for T1DM and the first therapy aimed at delaying the clinical onset of any immune-mediated disease represents a paradigm shift in the treatment of T1DM.
The 7-transmembrane G protein-coupled receptor GPR30 has been recognized as a G protein-coupled oestrogen receptor (GPER) since 2008. This Review discusses progress in GPER research in physiology and disease and its potential implications for clinical medicine.
More genetic variants associated with type 2 diabetes mellitus are being identified. This Perspective article outlines various tools and platforms that can be applied to prioritize candidate genes associated with an increased risk of disease for functional validation.
This Review highlights the latest advances in our understanding of the mechanisms of action of metformin. Potential repurposing of metformin for other indications is also discussed.
